Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?
暂无分享,去创建一个
E. Wattel | P. Fenaux | F. Bauters | J. Laï | L. Detourmignies | P. Fenaux | Françis Bauters | J. L. Lai
[1] W. Hiddemann,et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. , 1991, Blood.
[2] H. Dohy,et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.
[3] H. Tilly,et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Gerhartz,et al. Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group. , 1989, Bone marrow transplantation.
[5] B. Löwenberg,et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Beuscart,et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.
[7] Edward J. Lee,et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.
[8] B. Coiffier,et al. Treatment of acute myeloid leukemia in elderly patients. A retrospective study , 1988, Cancer.
[9] A. Ganser,et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. , 1989, Blood.
[10] R. Gale,et al. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. , 1987, Leukemia.
[11] R. Simon,et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. H. Cowan,et al. Low dose cytosine arabinoside in acute myeloid leukemia: Remission is not due to differentiation induction , 1985, American journal of hematology.
[13] F. Sigaux,et al. Low‐dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients , 1985, Cancer.
[14] F. Lacombe,et al. Relationship between patients' age, bone marrow karyotype, and outcome of induction therapy in acute myelogenous leukemia , 1985, American journal of hematology.
[15] F. Sigaux,et al. Treatment of leukemia with low-dose ara-C: a study of 160 cases. , 1985, Seminars in oncology.
[16] H. Tilly,et al. Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? , 1983, Blood.
[17] C. Bloomfield,et al. Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia. , 1984, Cancer genetics and cytogenetics.
[18] M. Baccarani,et al. DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPY , 1979, British journal of haematology.
[19] L. Sachs,et al. THE DIFFERENTIATION OF MYELOID LEUKAEMIA CELLS: NEW POSSIBILITIES FOR THERAPY , 1978, British journal of haematology.
[20] C. Spurr,et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.